Ignite Creation Date:
2025-12-25 @ 5:05 AM
Ignite Modification Date:
2025-12-26 @ 4:08 AM
Study NCT ID:
NCT00788918
Status:
COMPLETED
Last Update Posted:
2013-01-11
First Post:
2008-11-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D019698', 'term': 'Hepatitis C, Chronic'}, {'id': 'D003072', 'term': 'Cognition Disorders'}, {'id': 'D015673', 'term': 'Fatigue Syndrome, Chronic'}, {'id': 'D003865', 'term': 'Depressive Disorder, Major'}, {'id': 'D060825', 'term': 'Cognitive Dysfunction'}], 'ancestors': [{'id': 'D006526', 'term': 'Hepatitis C'}, {'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D006525', 'term': 'Hepatitis, Viral, Human'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018178', 'term': 'Flaviviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D006521', 'term': 'Hepatitis, Chronic'}, {'id': 'D006505', 'term': 'Hepatitis'}, {'id': 'D008107', 'term': 'Liver Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D009135', 'term': 'Muscular Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D004679', 'term': 'Encephalomyelitis'}, {'id': 'D000090862', 'term': 'Neuroinflammatory Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D003866', 'term': 'Depressive Disorder'}, {'id': 'D019964', 'term': 'Mood Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D007372', 'term': 'Interferons'}, {'id': 'D012254', 'term': 'Ribavirin'}, {'id': 'C100416', 'term': 'peginterferon alfa-2a'}], 'ancestors': [{'id': 'D016207', 'term': 'Cytokines'}, {'id': 'D036341', 'term': 'Intercellular Signaling Peptides and Proteins'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D001685', 'term': 'Biological Factors'}, {'id': 'D012263', 'term': 'Ribonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 100}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2008-11'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-01', 'completionDateStruct': {'date': '2012-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2013-01-10', 'studyFirstSubmitDate': '2008-11-10', 'studyFirstSubmitQcDate': '2008-11-10', 'lastUpdatePostDateStruct': {'date': '2013-01-11', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2008-11-11', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2012-11', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Neuropsychological test results, cytokine profile and MRI findings', 'timeFrame': '8 weeks before starting IFN+RIB therapy', 'description': 'Assessment performed before starting antiviral treatment in patients with chronic hepatitis C who awaits treatment. HCV patients without pending treatment will be tested in conjunction with their outpatient controls.'}], 'secondaryOutcomes': [{'measure': 'Interferon-induced depression', 'timeFrame': '8-12 weeks after treatment inititation'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Chronic Hepatitis C', 'cognitive dysfunction', 'MRI', 'MR spectroscopy', 'interferon', 'ribavirin', 'sustained virologic response, major depressive disorder'], 'conditions': ['Hepatitis C, Chronic', 'Cognition Disorders', 'Fatigue Syndrome, Chronic', 'Major Depressive Disorder']}, 'referencesModule': {'references': [{'pmid': '17703362', 'type': 'BACKGROUND', 'citation': 'Perry W, Hilsabeck RC, Hassanein TI. Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci. 2008 Feb;53(2):307-21. doi: 10.1007/s10620-007-9896-z. Epub 2007 Aug 17.'}, {'pmid': '18538439', 'type': 'BACKGROUND', 'citation': "Forton DM, Hamilton G, Allsop JM, Grover VP, Wesnes K, O'Sullivan C, Thomas HC, Taylor-Robinson SD. Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. J Hepatol. 2008 Sep;49(3):316-22. doi: 10.1016/j.jhep.2008.03.022. Epub 2008 Apr 25."}, {'pmid': '15793853', 'type': 'BACKGROUND', 'citation': 'McAndrews MP, Farcnik K, Carlen P, Damyanovich A, Mrkonjic M, Jones S, Heathcote EJ. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology. 2005 Apr;41(4):801-8. doi: 10.1002/hep.20635.'}, {'pmid': '16271658', 'type': 'BACKGROUND', 'citation': "Golden J, O'Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry. 2005 Nov-Dec;27(6):431-8. doi: 10.1016/j.genhosppsych.2005.06.006."}, {'pmid': '16251811', 'type': 'BACKGROUND', 'citation': 'Laskus T, Radkowski M, Adair DM, Wilkinson J, Scheck AC, Rakela J. Emerging evidence of hepatitis C virus neuroinvasion. AIDS. 2005 Oct;19 Suppl 3:S140-4. doi: 10.1097/01.aids.0000192083.41561.00.'}], 'seeAlsoLinks': [{'url': 'http://www.cfin.au.dk/', 'label': 'Center for Functionally Integrative Neuroscience, Aarhus University Hospital'}, {'url': 'http://psykiatriskforskning.dk/', 'label': 'Center for Psychiatric Research, Aarhus University Hospital'}]}, 'descriptionModule': {'briefSummary': 'Patients with HCV infection often suffer from chronic fatigue, depression and reduced cognition, even before evolving severe liver fibrosis, liver cirrhosis and hepatic encephalopathy.\n\nIt is currently unclear to what extent the symptoms er due to a direct pathological effects of the virus itself, or due to pre-existing psychiatric disease. There is a complex relationship between prior or existing drug abuse, psychiatric disease and HCV infection, that makes it difficult to establish cause-effect relationships.\n\nA biological mechanism has been suggested to contribute to development of cerebral dysfunction in the patients. According to the prevailing Trojan Horses hypothesis circulating lymphocytes cross the blood brain barrier carrying HCV to the central nervous system and virus is subsequently replicated in the macrophages and the microglia in brain as a separate compartment. As part of the immunological response to viral replication, neurodegenerative processes takes place with a harmful effect on the neural circuit and cerebral function. Identification of HCV RNA negative strand, a replication product, in brain tissue from HCV patients, as part of autopsy studies, supports the hypothesis. Moreover, HCV patients have also been observed with abnormal metabolic concentrations in the frontal white substance and the basal ganglia by MRI spectroscopy compared to control groups.\n\nThe overall study objective is to assess cerebral function with particular emphasis on cognitive functions in HCV patients (genotypes 1,2,3 and 4) by use of a neuropsychiatric test battery. Furthermore, the patients will be examined by MRI, including magnetization transfer, diffusion tensor and contrast perfusion, in order to perform measurements of cerebral volumetric and microstructure. Finally, HCV analysis, including viral sequences and cytokine profiles, in serum and cerebrospinal fluid will be carried out in the study population.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '60 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Chronic HCV infection with genotype 1, 2, 3 or 4.\n* Age \\> 18 and \\<60\n* Liver biopsy or fibroscan performed within last 5 years\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Liver biopsy showing liver pathology not due to HCV infection.\n* Liver cirrhosis or severe liver fibrosis\n* Former antiviral HCV treatment (for included HCV patients).\n* HIV and/or Hepatitis B virus infection.\n* Alcohol or drug abuse within the last 2 years.\n* Neutropenia, anemia or thrombocytopenia.\n* Clinical signs of non-compensated liver pathology.\n* Moderate to severe cardiopulmonary disease (NYHA score 1 or above)\n* Creatinine clearance \\< 80mL/min.\n* Pregnancy.\n* Ferromagnetic implants\n* Significant somatic disease affecting the central nervous system (somatic/neurologic disease)\n* Head trauma resulting in unconsciousness \\> 5min\n* Schizophrenia or other psychotic disorders'}, 'identificationModule': {'nctId': 'NCT00788918', 'briefTitle': 'Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)', 'organization': {'class': 'OTHER', 'fullName': 'University of Aarhus'}, 'officialTitle': 'Study of Cerebral Function in Patients With Chronic Hepatitis C Infection Before and After Pegylated Interferon Alfa-2a and Ribavirin Therapy', 'orgStudyIdInfo': {'id': 'SKS-0078-HCVCNS'}, 'secondaryIdInfos': [{'id': 'EudraCT 2007-005707-18'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Chronic hepatitis C treatment', 'description': '30 Chronic HCV patients with pending antiviral treatment. A majority will have pending treatment with interferon and ribavirin, and the treated patients will be assessed 8-12 weeks after starting treatment for interferon-induced depression.', 'interventionNames': ['Drug: Interferon and ribavirin']}, {'type': 'NO_INTERVENTION', 'label': 'Healthy Controls', 'description': '50 age, sex and education matched controls (matched 1:1 to participants in the HCV patient groups (+/- treatment)'}, {'type': 'NO_INTERVENTION', 'label': 'Former HCV infected', 'description': '20 Subjects with prior HCV infection identified through positive HCV antibodies, but negative HCV RNA.'}, {'type': 'NO_INTERVENTION', 'label': 'Chronic HCV patient - no treatment', 'description': '20 chronic HCV patients without pending antiviral treatment.'}], 'interventions': [{'name': 'Interferon and ribavirin', 'type': 'DRUG', 'otherNames': ['Pegasys (ATC Code: L03AB11) and Copegus (ATC Code: J05AB04)'], 'description': 'Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.', 'armGroupLabels': ['Chronic hepatitis C treatment']}]}, 'contactsLocationsModule': {'locations': [{'zip': '8200', 'city': 'Aarhus', 'state': 'Jylland', 'country': 'Denmark', 'facility': 'Department of Infectious Diseases, Aarhus University Hospital, Skejby', 'geoPoint': {'lat': 56.15674, 'lon': 10.21076}}], 'overallOfficials': [{'name': 'Peter Leutscher, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Aarhus University Hospital, Dept. Infectious Diseases'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Aarhus University Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}